Smith & Nephew PLC
LSE:SN

Watchlist Manager
Smith & Nephew PLC Logo
Smith & Nephew PLC
LSE:SN
Watchlist
Price: 1 239 GBX -1.86%
Market Cap: £10.6B

Smith & Nephew PLC
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Smith & Nephew PLC
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Smith & Nephew PLC
LSE:SN
EPS (Diluted)
$0
CAGR 3-Years
40%
CAGR 5-Years
7%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
EPS (Diluted)
-$4
CAGR 3-Years
-40%
CAGR 5-Years
9%
CAGR 10-Years
N/A
EKF Diagnostics Holdings PLC
LSE:EKF
EPS (Diluted)
£0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
EPS (Diluted)
£0
CAGR 3-Years
17%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Inspiration Healthcare Group PLC
LSE:IHC
EPS (Diluted)
£0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-21%
EMV Capital PLC
LSE:EMVC
EPS (Diluted)
£0
CAGR 3-Years
8%
CAGR 5-Years
N/A
CAGR 10-Years
8%
No Stocks Found

Smith & Nephew PLC
Glance View

Smith & Nephew PLC, a name synonymous with innovation in the medical technology sphere, began its journey in the late 19th century in the quaint city of Kingston upon Hull, England. This humble pharmaceutical shop evolved over time into a global leader in medical devices, driven by a commitment to improve people's quality of life through pioneering healthcare solutions. Today, the company stands as a key player in three core sectors: orthopedics, advanced wound management, and sports medicine. By focusing on these specialized areas, Smith & Nephew has set itself apart, effectively addressing the complex challenges faced by aging populations and a rising demand for minimally invasive treatments. Revenue streams pour in from their innovative products, which cater to both healthcare professionals and patients worldwide. In orthopedics, they make significant headway with implants and instruments used in hip and knee replacements, essential solutions in addressing joint deterioration and injury. Their advanced wound management division tackles issues from chronic wounds to burns, supplying dressings and delivery systems designed for optimal healing. Meanwhile, the sports medicine segment contributes by offering arthroscopy and enabling technologies, crucial for athletic injury prevention and recovery. By maintaining a strong pipeline of research and development initiatives, Smith & Nephew continues to enhance its offerings, pushing the envelope in medical technology and consequently fortifying its financial foundation.

SN Intrinsic Value
1 111.74 GBX
Overvaluation 10%
Intrinsic Value
Price GBX1 239

See Also

What is Smith & Nephew PLC's EPS (Diluted)?
EPS (Diluted)
0.7 USD

Based on the financial report for Dec 31, 2025, Smith & Nephew PLC's EPS (Diluted) amounts to 0.7 USD.

What is Smith & Nephew PLC's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
7%

Over the last year, the EPS (Diluted) growth was 53%. The average annual EPS (Diluted) growth rates for Smith & Nephew PLC have been 40% over the past three years , 7% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett